Pediatr. praxi. 2009;10(4):227-232
Trends in prevention of pneumococcal infections in children
- Katedra epidemiologie, Fakulta vojenského zdravotnictví, Hradec Králové
Immunization against pneumococci creates today already a cornerstone of immunization calendars in vast majority of developed countries
worldwide. A major reduction of invasive pneumococcal diseases in US is possible to consider as quite unquestionable success. In
the course of few years all problems seem not to be solved. Serotype 19A is a major issue in US, which otherwise did not disprove the
total benefit, however no doubts it limits overall impact. Similarly a replacement with non-vaccine serotypes in some other countries
decreases overall efficacy of such a provision. Future vaccines will have indeed extended coverage, however question is, if even they
solve all unanswered questions fully or it will be necessary to use different type of vaccines, e.g. protein.
Keywords: immunization calendar, IPD, pneumococcal conjugated vaccine, S. pneumoniae.
Published: October 1, 2009 Show citation
References
- Prymula R, Pospíšilová K. Současné přístupy k očkování konjugovanou pneumokokovou vakcínou. Prakt Lék 2008; 88(2): 106-109.
- Dinleyici EC, Yargic ZA. Pneumococcal conjugated vaccines: impact of PCV-7 and new achievements in the postvaccine era. Expert Rev Vaccines. 2008; 7(9): 1367-1394.
Go to original source... 
Go to PubMed... - O'Brien KL, Santosham M. Potential impact of conjugate pneumococcal vaccines on pediatric pneumococcal diseases. Am J Epidemiol 2004; 159: 634-644. Go to original source... Go to PubMed...
- World Health Organization Recommendations for production and control of pneumococcal conjugate vaccines. WHO Technical Report Series 2005; 927: 2.
- Henckaerts I, Durant N, De Grave D, Schuerman L, Poolman J. Validation of Routine High-throughput Pneumococcal Opsonophagocytosis Assays. Link with Clinical Efficacy. (Abstract DT.07). In: Proceedings of the Program and Abstracts of the 5th International Symposium on Pneumococci and Pneumococcal Diseases. Alice Springs (Australia); 2-6 April 2006.
- Ruan MR, Akkoyunlu M, Grubb A, Forsgren A. Protein D of Haemophilus influenzae. A novel bacterial surface protein with affinity for human IgD. J Immunol 1990; 145: 3379-3384. Go to original source...
- Křížová P, Prymula R, Marešová V, Motlová J, Beneš C. Pneumokoková onemocnění. Pediatr. pro Praxi 2009; 10(Suppl. B): 45 s.
- Prymula R, Peeters P, Chrobok V, Kriz P, Novakova E, Kaliskova E, et al. Pneumococcal capsular polysaccharides conjugated to protein D provide protection against otitis media caused by both Streptococcus pneumoniae and nontypable Haemophilus influenzae. Lancet 2006; 367: 740-748. Go to original source... Go to PubMed...
- Poolman J, Kriz P, Feron Ch, Di-Paolo E, Henckaerts I, Miseur A, et al. Pneumococcal serotype 3 otitis media, limited effect of polysaccharide conjugate immunisation and strain characteristics. Vaccin 2009; 27: 3213-3222. Go to original source... Go to PubMed...
- Prymula R, Chlibek R, Splino M, Kaliskova E, Kohl I, Lommel P, et al. Safety of the 11-valent pneumococcal vaccine conjugated to non-typeable Haemophilus influenzae-derived protein D in the first 2 years of life and immunogenicity of the co-administered hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio virus, Haemophilus influenzae type b and control hepatitis A vaccines. Vaccine 2008; 26(35): 4563-4570. Go to original source... Go to PubMed...
- Chevallier B, Vesikari T, Brzostek J, Knuf M, Bermal N, Aristegui J, et al. Safety and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines. Pediatr Infect Dis J. 2009; 28(4 Suppl): S109-118. Go to original source... Go to PubMed...